Owkin is a developer of machine learning tools designed to augment medical and biological research. The company's tool integrates biomedical images, genomics and clinical data in order to discover mechanisms and biomarkers associated with diseases and treatment outcomes and build models that are as interpretable as possible, for an understanding of the initial data and, through transfer learning, they push the intelligence of pre-trained algorithms into new models, enabling cohorts to have a data-based predictive model.
Owkin was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology and Gilles Wainrib, PhD, a pioneer in the field of Artificial Intelligence in biology.
Owkin develops scientific collaborations with medical institutions and partners with pharmaceutical companies. Through these partnerships, Owkin has developed a federated learning technology in healthcare to overcome the data sharing problem, building collective intelligence from distributed data at scale while preserving data privacy and security.
Owkin Socrates is Owkin's technology platform. Socrates is engineered to be usable by non machine learning experts to perform artificial intelligence projects and deliver production level predictive models. With the models, users can develop drug development stages, from survival prognosis to target discovery, patient recruitment for clinical trials to post-market analysis.
The Owkin Socrates platform is powered by machine learning and deep learning algorithms.
Owkin provides their experience in artificial intelligence and machine learning to their partners to help their partners research and development skills for existing and future data analytics. The services include data science, technology assessments, specific target and molecule discover projects and real-world data for clinical trial optimization.
Owkin announced the close of their seed round on October 30, 2016 with a raised total of $2.1 million. Participation in the round came from Shana Fisher, Nicole Junkermann, NJF Capital, Jorg Mohaupt, Jean-Paul Clozel and Brent Hoberman.
Owkin announced the first close of their Series A financing on January 16, 2018 with a raised total of $11 million. Otium Capital led the round, which included participation from Plug and Play, NJF Capital and Cathay Innovation.
Owkin announce the second close of their Series A financing on May 23, 2018 with a raised total of $5 million from GV.
On March 7, 2019 Owkin announced the close of an undisclosed funding round with an undisclosed raised amount. F-Prime led the financing round, which included participation from NJF Capital, GV, Eight Roads Ventures and Cathay Innovation.
Partnership aims to connect UK hospitals with AI 'federated learning'
Owkin, NVIDIA team up to deliver AI to hospitals
Owkin Publishes Research in Nature Medicine
Owkin's mesothelioma AI discovers new biomarkers from lung biopsy images
OWKIN announces an AI-powered medical research network.
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Owkin launches global patient data sharing network for training AIs
Earlier this year, the New York-based Owkin raised about $16 million through a series A funding round led by Otium Venture.
Adrian Gonzalez Lopez
Chief Technology Officer
Alberto Romagnoni, PhD
Translational Research Scientist
Employee Experience Manager
Andre Manoel, PhD
Machine Learning Scientist
Chief Operating Officer
Head of Strategy
Beniot Schmauch, PhD
Senior Data Scientist
Camille Marini, PhD
Vice President of Engineering
Senior Partnership Manager
Substra Senior Project Manager
Substra Devops Engineer
Head of Pharma Research and Development Projects
Derek T. Russell-Kraft
Elodie Pronier, PhD
Translational Research Scientist
Eric Tramel, PhD
Group Lead, Federated Learning
Documentaries, videos and podcasts
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- CompanyA company, abbreviated 'co.', is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.